Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A prospective observational multi centre research study in GP practices clustered within up to 10 UK Primary care trusts.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes

Exclusion Criteria:

• Patients who are currently receiving other maintenance therapy (except LAMA) for COPD.

• Patients previously prescribed Indacaterol.